EUVIMEDDescoperă EUVIMED
Crossref

Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation

Shigeki Kusamura iD, Edward Levine, Michela Cinquini iD, Olivier Glehen, Pompiliu Piso, Andreas Brandl iD, Claudio Quadros iD, Marc Pocard, Faheez Mohamed, Clarice Eveno, Dario Baratti, Marcello Guaglio iD and 2 more

Journal of Surgical Oncology · 2025-10 · 132 (5) · 810-816

DOI: 10.1002/jso.28167 ↗

At a glance

Journal article in Journal of Surgical Oncology, published online on 2025-08-16. Written by Shigeki Kusamura and 13 co-authors. Institution: Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milano, Lombardia, Italy. Major MEDLINE topics: Pseudomyxoma Peritonei, Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Neoplasms. Cited 6 times so far (Crossref); 50 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Introduction

Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucinous ascites and peritoneal implants, primarily arising from ruptured appendiceal neoplasms. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the preferred treatment for resectable and operable cases.

Methods

An international panel from the Peritoneal Surface Oncology Group International (PSOGI), the International Society for the Study of Pleura and Peritoneum (ISSPP), the Society of Surgical Oncology (SSO), the European Society of Surgical Oncology (ESSO), and EURACAN used the GRADE methodology and ADOLOPMENT approach to adapt existing guidelines. Clinical questions were framed using the PICO framework, and systematic reviews were conducted. Evidence certainty and the balance of benefits and harms were evaluated with the Evidence‐to‐Decision framework.

Results

A strong recommendation was made for CRS and HIPEC over debulking surgery for resectable PMP. Observational studies reported 5‐ and 10‐year survival rates of 80% and 55%, respectively, with CRS and HIPEC, compared to lower outcomes with debulking. Despite the very low certainty of evidence, the panel strongly endorses CRS and HIPEC over debulking surgery. This recommendation is driven by PMP's known chemoresistance, the lack of viable alternative treatments, and the survival benefits observed in observational studies coming only from radical surgery.

Conclusion

This consensus endorses CRS and HIPEC as the standard of care for operable and resectable PMP. This recommendation will increase acceptance and awareness among a broader audience of healthcare professionals about the potential benefits of this treatment in managing this rare peritoneal disease.

Subjects

MeSH terms (MEDLINE)

Pseudomyxoma PeritoneiCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyPeritoneal NeoplasmsPractice Guidelines as TopicHyperthermia, InducedHumansCombined Modality Therapy

Author keywords

GRADEconsensuscytoreductive surgery and HIPECmultiscocietypseudomyxoma peritonei

Authors and institutions

  • Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milano, Lombardia, Italy.
  • Section of Surgical Oncology, Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Clinical Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Lombardia, Italy.
  • Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Chirurgie Digestive, Lyon, Auvergne-Rhône-Alpes, France.
  • Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Bavaria, Germany.
  • Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Baden-Württemberg, Germany.

ORCID profiles: Shigeki Kusamura, Michela Cinquini, Andreas Brandl, Claudio Quadros, Marcello Guaglio

Cite

APA

Kusamura, S., Levine, E., Cinquini, M., Glehen, O., Piso, P., Brandl, A., Quadros, C., Pocard, M., Mohamed, F., Eveno, C., Baratti, D., Guaglio, M., Deraco, M., & Moran, B. (2025). Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation. Journal of Surgical Oncology, 132(5), 810-816. https://doi.org/10.1002/jso.28167

Vancouver

Kusamura S, Levine E, Cinquini M, Glehen O, Piso P, Brandl A, et al. Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation. Journal of Surgical Oncology. 2025;132(5):810-816. doi:10.1002/jso.28167

BibTeX
@article{Kusamura2025,
  author = {Kusamura, Shigeki and Levine, Edward and Cinquini, Michela and Glehen, Olivier and Piso, Pompiliu and Brandl, Andreas and Quadros, Claudio and Pocard, Marc and Mohamed, Faheez and Eveno, Clarice and Baratti, Dario and Guaglio, Marcello and Deraco, Marcello and Moran, Brendan},
  title = {Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  volume = {132},
  number = {5},
  pages = {810--816},
  doi = {10.1002/jso.28167}
}
Start for free →